首页> 外文期刊>中国神经再生研究(英文版) >Assessment of structural brain changes in patients with type 2 diabetes mellitus using the MRI-based brain atrophy and lesion index
【24h】

Assessment of structural brain changes in patients with type 2 diabetes mellitus using the MRI-based brain atrophy and lesion index

机译:

获取原文
获取原文并翻译 | 示例
       

摘要

Patients with type 2 diabetes mellitus(T2 DM) often have cognitive impairment and structuralbrain abnormalities.The magnetic resonance imaging(MRI)-based brain atrophy and lesion index can be used to evaluate common brain changes and their correlation with cognitive function,and can therefore also be used to reflect whole-brain structural changes related to T2 DM.A total of 136 participants(64 men and 72 women,aged 55–86 years) were recruited for our study between January 2014 and December 2016.All participants underwent MRI and Mini-Mental State Examination assessment(including 42 healthy control,38 T2 DM without cognitive impairment,26 with cognitive impairment but without T2 DM,and 30 T2 DM with cognitive impairment participants).The total and sub-category brain atrophy and lesion index scores in patients with T2 DM with cognitive impairment were higher than those in healthy controls.Differences in the brain atrophy and lesion index of gray matter lesions and subcortical dilated perivascular spaces were found between non-T2 DM patients with cognitive impairment and patients with T2 DM and cognitive impairment.After adjusting for age,the brain atrophy and lesion index retained its capacity to identify patients with T2 DM with cognitive impairment.These findings suggest that the brain atrophy and lesion index,based on T1-weighted and T2-weighted imaging,is of clinical value for identifying patients with T2 DM and cognitive impairment.Gray matter lesions and subcortical dilated perivascular spaces may be potential diagnostic markers of T2 DM that is complicated by cognitive impairment.This study was approved by the Medical Ethics Committee of University of South China(approval No.USC20131109003) on November 9,2013,and was retrospectively registered with the Chinese Clinical Trial Registry(registration No.Chi CTR1900024150) on June 27,2019.

著录项

  • 来源
    《中国神经再生研究(英文版)》 |2022年第3期|618-624|共7页
  • 作者单位

    Department of Radiology Shengjing Hospital of China Medical University Shenyang Liaoning Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology Shengjing Hospital of China Medical University Shenyang Liaoning Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

    Department of Radiology The First Affiliated Hospital of University of South China Hengyang Hunan Province China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号